...
首页> 外文期刊>The oncologist >Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation
【24h】

Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation

机译:甲基泼尼松龙旋转治疗地塞米松引起的化疗打h

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Dexamethasone-induced hiccup (DIH) is an underrecognized symptom in patients with cancer, and little information is available about its treatment. The aims of this study were to investigate the feasibility of methylprednisolone rotation as treatment and to confirm the male predominance among those with cancer who experienced DIH during chemotherapy. Methods. Persons with cancer who experienced hiccups during chemotherapy treatment and who were receiving treatment with dexamethasone were presumed to have DIH. The following algorithmic practicewasimplementedfor antiemetic corticosteroid use: rotation from dexamethasone to methylprednisolone in the next cycle and dexamethasone re-administration in the second cycle of chemotherapy after recognition of hiccups to confirm DIH. All other antiemetics except corticosteroid remained unchanged. Patients (n40) were recruited from eight cancercentersinKoreafromSeptember2012toApril2013.Data were collected retrospectively. Results. Hiccup intensity (numeric rating scale [NRS]: 5.38 vs. 0.53) and duration (68.44 minutes vs. 1.79 minutes) were significantly decreased after rotation to methylprednisolone, while intensity of emesis was not increased (NRS: 2.63 vs. 2.08). Median dose of dexamethasone and methylprednisolone were 10 mg and 50 mg, respectively. Thirty-four (85%) of 40 patientsshowed complete resolution of hiccups after methylprednisolone rotation in the next cycle. Of these 34 patients, 25 (73.5%) had recurrence of hiccups after dexamethasone re-administration. Compared with baseline values, hiccup intensity (NRS: 5.24 vs. 2.44)andduration(66.43minutesvs.22.00minutes)weresignificantly attenuated after dexamethasone re-administration. Of the 40 eligible patients, 38 (95%) were male. Conclusion. DIH during chemotherapy could be controlled without losing antiemetic potential by replacing dexamethasone with methylprednisolone.Wealso identified a male predominanceof DIH. Further prospective studies are warranted.
机译:背景。地塞米松诱发的打cup(DIH)是癌症患者中未被充分认识的症状,关于其治疗的信息很少。这项研究的目的是调查甲基强的松龙旋转治疗的可行性,并确认在化疗期间经历过DIH的癌症患者中男性占多数。方法。假定在化疗期间出现打h并接受地塞米松治疗的癌症患者患有DIH。对于止吐皮质类固醇的使用,实施了以下算法实践:在下一周期从地塞米松旋转至甲基泼尼松龙,在识别出打to以确认DIH后,在化疗的第二个周期再次给予地塞米松。除皮质类固醇外,所有其他止吐药均未改变。从2012年9月至2013年4月在韩国的8个癌症中心招募患者(n40)。结果。旋转至甲基强的松龙后,打intensity强度(数字等级量表[NRS]:5.38对0.53)和持续时间(68.44分钟对1.79分钟)显着减少,而呕吐强度没有增加(NRS:2.63对2.08)。地塞米松和甲基泼尼松龙的中位剂量分别为10 mg和50 mg。 40名患者中的34名(85%)在下一个周期中甲基强的松龙旋转后显示出完全的打resolution症状。在这34例患者中,有25例(73.5%)在地塞米松再次给药后出现打h复发。与基线值相比,地塞米松重新给药后,打ic强度(NRS:5.24 vs. 2.44)和持续时间(66.43分钟vs.22.00分钟)明显减轻。在40名合格患者中,有38名(95%)是男性。结论。通过用甲基强的松龙代替地塞米松,可以控制化疗期间的DIH,而不会失去止吐药的潜力。我们还发现了男性占主导地位的DIH。有必要进行进一步的前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号